Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates?

Journal of Applied Toxicology

Volumn 35, Issue 9, 2015, Pages 1017-1029

  Mesens, Natalie ^a   Crawford, Alexander D ^b,d   Menke, Aswin ^c   Hung, Pham Duc ^b   Van Goethem, Freddy ^a   Nuyts, Rik ^b   Hansen, Erik ^a   Wolterbeek, Andre ^c   Van Gompel, Jacky ^a   De Witte, Peter ^b   Esguerra, Camila V ^b,e  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c TNO   (Netherlands)

^d UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

DILI; Hepatotoxicity; Lfabp10a; Screening assay; Zebrafish larvae

Indexed keywords

ALPIDEM; AMIODARONE; BOSENTAN; BUSPIRONE; DICLOFENAC; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 10A; GLYCOGEN; KETOROLAC; NEFAZODONE; PARACETAMOL; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TACRINE; TAMOXIFEN; TETRACYCLINE; TROGLITAZONE; UNCLASSIFIED DRUG; ZOLPIDEM; DRUG; FATTY ACID-BINDING PROTEIN 10, ZEBRAFISH; ZEBRAFISH PROTEIN;

ADULT; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CHOLESTASIS; CIRCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GLYCOGEN ANALYSIS; HEART RATE; HISTOLOGY; HISTOPATHOLOGY; IN SITU HYBRIDIZATION; LARVAL STAGE; LIVER CELL; LIVER LEVEL; LIVER SIZE; LIVER TOXICITY; MALE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL TOXICITY; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATOSIS; TOXICITY TESTING; ZEBRA FISH; ANIMAL; ANIMAL TESTING ALTERNATIVE; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION; GENETICS; LARVA; LIVER; METABOLISM; PHYSIOLOGY; PROCEDURES; STATISTICAL MODEL;

DANIO RERIO;

ANIMAL USE ALTERNATIVES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FATTY ACID-BINDING PROTEINS; GENE EXPRESSION; IN SITU HYBRIDIZATION; LARVA; LIVER; LOGISTIC MODELS; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84937887298     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.3091     Document Type: Article

References (48)

1. Agresti A. 2002. Categorical Data Analysis, 7th edn. John Wiley & Sons, Inc.: Hoboken, New Jersey.
2. Alderton W, Berghmans S, Butler P, Chassaing H, Fleming A, Golder Z, Richards F, Gardner I. 2010. Accumulation and metabolism of drugs and CYP probe substrates in zebrafish larvae. Xenobiotica 40: 547-557.
3. Amali AA, Rekha RD, Lin CJ, Wang WL, Gong HY, Her GM, Wu JL. 2006. Tioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J. Biomed. Sci. 13: 225-232.
4. Atshaves BP, Martin GG, Hostetler HA, McIntosh AL, Kier AB, Schroeder F. 2010. Liver fatty acid-binding protein and obesity. J. Nutr. Biochem. 2: 1015-1032.
5. Braunbeck T, Gorge G, Storch V, Nagel R. 1990. Hepatic steatosis in zebrafish (Brachydanio rerio) induced by long-term exposure to gamma-hexachlorocyclohexane. Ecotoxicol. Environ. Saf. 19: 355-374.
6. Chakraborty C, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G. 2009. Zebrafish: a complete animal model for in vivo drug discovery and development. Curr. Drug Metab. 10: 116-124.
7. Chng HT, Ho HK, Yap CW, Lam SH, Chan EC. 2012. An Investigation of the Bioactivation Potential and Metabolism Profile of Zebrafish versus Human. J. Biomol. Screen. 7: 974-986.
8. Chu J, Sadler KC. 2009. New school in liver development: lessons from zebrafish. Hepatology 50: 1656-1663.
9. th European Regional ISSX meeting, Noordwijk aan Zee, The Netherlands, June 17-21.
10. Dykens JA, Will Y. 2007. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12: 777-785.
11. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69: 223-231.
12. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG. 2013. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch. Toxicol. 87: 1315-1530.
13. Guengerich FP, Shimada T. 1991. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes. Chem. Res. Toxicol. 4: 391-407.
14. Hartung T, Daston G. 2009. Are in vitro tests suitable for regulatory use? Toxicol. Sci. 111: 233-237.
15. Hill A, Mesens N, Steemans M, Xu JJ, Aleo MD. 2012. Comparisons between in vitro whole cell imaging and in vivo zebrafish-based approaches for identifying potential human hepatotoxicants earlier in pharmaceutical development. Drug Metab. Rev. 44: 127-140.
16. Hinton DE, Segner H, Braunbeck T. 2001. Toxic responses of the liver. In Target Organ Toxicity in Marine and Freshwater Teleosts: Organs, Schlenk D, Benson WH (eds). Taylor & Francis: London; 224-268.
17. Isogai S, Horiguchi M, Weinstein BM. 2001. The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev. Biol. 230: 278-301.
18. Jollow DJ, Mitch JR, Potter WZ. 1973. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 187: 195-202.
19. Jones HS, Panter GH, Hutchinson TH, Chipman JK. 2010. Oxidative and conjugative xenobiotic metabolism in zebrafish larvae in vivo. Zebrafish 7: 23-30.
20. Kaplowitz N. 2005. Idiosyncratic drug hepatotoxicity. Nat. Rev. Discov. 4: 489-499.
21. Kaplowitz N. 2007. Mechanisms of liver injury. In Drug-induced Liver Disease, 2nd edn, Kaplowitz N, DeLeve LD (eds). Informa HealthCare: New York; 3-13.
22. Khetani SR, Bhatia SN. 2008. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26: 120-126.
23. Korzh S, Pan X, Garcia-Lecea M, Winata CL, Pan X, Wohland T, Korzh V, Gong Z. 2008. Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafish. BMC Dev. Biol. 8: 84.
24. MacDonald JS, Robertson RT. 2009. Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol. Sci. 110: 40-46.
25. Martin GG, Huang H, Atshaves BP, Binas B, Schroeder F. 2003. Ablation of the liver fatty acid binding protein gene decreases fatty acyl CoA binding capacity and alters fatty acyl CoA pool distribution in mouse liver. Biochemistry 42: 11520-11532.
26. Menke AL, Spitsbergen JM, Wolterbeek AP, Woutersen RA. 2011. Normal anatomy and histology of the adult zebrafish. Toxicol. Pathol. 39: 759-775.
27. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W. 2010. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc. Natl. Acad. Sci. U. S. A. 40: 17315-17320.
28. Pack M, Solnica-Krezel L, Malicki J, Neuhauss SC, Schier AF, Stemple DL, Driever W, Fishman MC. 1996. Mutations affecting development of zebrafish digestive organs. Development 123: 321-328.
29. Passeri MJ, Cinaroglu A, Gao C, Sadler KC. 2009. Hepatic steatosis in response to acute alcohol exposure in zebrafish requires sterol regulatory element binding protein activation. Hepatology 49: 443-452.
30. Pessayre D, Berson A, Fromenty B. 2008. Features and mechanisms of drug-induced liver injury. In Drug-induced Mitochondrial Dysfunction, Dykens JA, Will Y (eds). John Wiley & Sons, Inc: Hoboken, New Jersey; 143-202.
31. Petinaria L, Kohnb LK, de Carvalhob JE, Genaria SC. 2004. Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Biol. Int. 28: 531-539.
32. Sabaliauskas NA, Foutz CA, Mest JR, Budgeon LR, Sidor AT, Gershenson JA, Joshi SB, Cheng KC. 2006. High-throughput zebrafish histology. Methods 39: 246-254.
33. Sadler KC, Amsterdam A, Soroka C, Boyer J, Hopkins N. 2005. A genetic screen in zebrafish identifies the mutants vps18, nf2 and foie gras as models of liver disease. Development 132: 3561-3572.
34. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE. 2012. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem. Res. Toxicol. 25: 2067-2082.
35. Schoonen WG, Westerink WM, Horbach GJ. 2009. High-throughput screening for analysis of in vitro toxicity. EXS 99: 401-452.
36. Spitsbergen JM, Kent ML. 2003. The state of the art of the zebrafish model for toxicology and toxicologic pathology research--advantages and current limitations. Toxicol. Pathol. 31: 62-87.
37. Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD. 2011. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem. Res. Toxicol. 24: 1345-1410.
38. Sukardi H, Chng HT, Chan EC, Gong Z, Lam SH. 2011. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Expert Opin. Drug Metab. Toxicol. 7: 579-589.
39. Thisse C, Thisse B. 2008. High-resolution in situ hybridization to whole-mount zebrafish embryos. Nat. Protoc. 3: 59-69.
40. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG. 2012. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. Toxicol. 25: 1616-1632.
41. Tsao-Wu GS, Weber CH, Budgeon LR, Cheng KC. 1998. Agarose-embedded tissue arrays for histologic and genetic analysis. Biotechniques 25: 614-618.
42. Ung CY, Lam SH, Zhang X, Li H, Ma J, Zhang L, Li B, Gong Z. 2011. Existence of inverted profile in chemically responsive molecular pathways in the zebrafish liver. Plos One 6: 27819.
43. Venkatachalam AB, Thisse C, Thisse B, Wright JM. 2009. Differential tissue-specific distribution of transcripts for the duplicated fatty acid-binding protein 10 (lfabp10a) genes in embryos, larvae and adult zebrafish (Danio rerio). FEBS J. 22: 6787-6797.
44. Vliegenthart AD, Tucker CS, Del Pozo J, Dear JW. 2014. Zebrafish as model organisms for studying drug induced liver injury. Br. J. Clin. Pharmacol. DOI: 10.1111/bcp.12408.
45. Wang WW, Khetani SR, Krzyzewski S, Duignan DB, Obach RS. 2010. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab. Dispos. 10: 1900-1905.
46. Wolf JC, Wolfe MJ. 2005. A brief overview of nonneoplastic hepatic toxicity in fish. Toxicol. Pathol. 33: 75-85.
47. Yamamoto T, Kikkawa R, Yamada H, Horii I. 2006. Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. J. Toxicol. Sci. 31: 49-60.
48. Zeilinger K, Schreiter T, Darnell M, Söderdahl T, Lübberstedt M, Dillner B, Knobeloch D, Nüssler AK, Gerlach JC, Andersson T. 2011. Scaling down of a clinical 3D perfusion multi-compartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng. Part C Methods 5: 549-556.